Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588609 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
A Phase 2 study, sponsored by Partner Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT05588609 is a Phase 2 study that was terminated before completion, run by Partner Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT05588609, a Phase 2 study, was terminated before completion, sponsored by Partner Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
Interventions
- DRUG Afatinib Oral Tablet
- DRUG Enzalutamide Pill
- DRUG Abiraterone acetate tablets
- BIOLOGICAL MCLA-128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05588609
The ClinicalTrials.gov registry entry for NCT05588609 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Partner Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Afatinib Oral Tablet is the first listed.
NCT05588609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05588609 about?
NCT05588609 is a clinical study titled "Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers". This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
What is the current status of trial NCT05588609?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-11-17. Estimated completion is 2025-07-03.
What interventions are being tested in trial NCT05588609?
The interventions under investigation include: Afatinib Oral Tablet (DRUG), Enzalutamide Pill (DRUG), Abiraterone acetate tablets (DRUG), MCLA-128 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05588609?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.